Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

PURPOSE: Talimogene laherparepvec (T-VEC) is an oncolytic immunotherapy designed to induce tumor regression of injected lesions through direct lytic effects, and of uninjected lesions through induction of systemic antitumor immunity. In this study, we describe the patterns and time course of respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Andtbacka, Robert H. I., Ross, Merrick, Puzanov, Igor, Milhem, Mohammed, Collichio, Frances, Delman, Keith A., Amatruda, Thomas, Zager, Jonathan S., Cranmer, Lee, Hsueh, Eddy, Chen, Lisa, Shilkrut, Mark, Kaufman, Howard L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Melanomas
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090012/
https://www.ncbi.nlm.nih.gov/pubmed/27342831
http://dx.doi.org/10.1245/s10434-016-5286-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090012/
https://www.ncbi.nlm.nih.gov/pubmed/27342831
http://dx.doi.org/10.1245/s10434-016-5286-0

Ejemplares similares